UK-432097
Based on 1 Customer Validation
UK-432097 is a highly potent and selective A2AAR agonist with a pKi of 8.4 for human A2AAR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research.
For research use only. We do not sell to patients.
- Purity: 98.9%
- CAS No.: 380221-63-6
- Formula: C40H47N11O6
- Molecular Weight:777.87
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Adenosine Receptor Isoforms
More
Biological Activity
pKi: 8.4 (A2AAR)[1]
UK-432097 has an EC50 value of 0.66 nM using CHO cells expressing human WT A50AR[1].
UK-432097 (0.01, 0.1, 1, 10, 100, 1000 nM; pretreated for 2 hours) significantly increases cAMP accumulation in CHO-A2A cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 380221-63-6
-
Appearance Solid
-
Molecular Weight 777.87
-
Formula C40H47N11O6
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](O[C@H](C(NCC)=O)[C@H]1O)N2C3=NC(C(NCCNC(NC4CCN(C5=CC=CC=N5)CC4)=O)=O)=NC(NCC(C6=CC=CC=C6)C7=CC=CC=C7)=C3N=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fei Xu, et al. Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7. [Content Brief]
[2]. Kenneth A Jacobson, et al. Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front Cell Neurosci. 2019 Mar 28;13:124. [Content Brief]
[3]. J Daniel Hothersall, et al. Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Mol Pharmacol. 2017 Jan;91(1):25-38. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
UK-432097 Related Classifications
HY-107046 Related Classifications
Powered by Bioz